Institute for Data Science in Oncology announces new focus-area lead for advancing data science to reduce public cancer burden
The Institute for Data Science in Oncology (IDSO) at The University of Texas MD Anderson Cancer Center today announced the appointment of Iakovos Toumazis, Ph.D., to lead its focused efforts in advancing decision analytics for health.
The goal of this new IDSO focus area is to develop, rigorously validate and implement advanced data‑driven analytics frameworks that support optimal decision‑making to enhance patient outcomes, to...
MD Anderson and SOPHiA GENETICS announce strategic collaboration to accelerate AI-driven precision oncology
The University of Texas MD Anderson Cancer Center and SOPHiA GENETICS today announced a strategic collaboration that unites SOPHiA GENETICS...
Three New Cancer Projects Receive Funding in Joint Collaboration Between Oden Institute, MD Anderson's IDSO and TACC
The University of Texas MD Anderson Cancer Center, the Oden Institute for Computational Engineering and Sciences, and the Texas Advanced Computing...
CPRIT awards MD Anderson over $29 million for prevention efforts, cancer research and faculty recruitment
The University of Texas MD Anderson Cancer Center today was awarded over $29 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of impactful prevention programs, groundbreaking cancer research efforts and faculty recruitment.
“We sincerely appreciate CPRIT for their continued support of cancer research and prevention at MD Anderson,” said Giulio Draetta, M.D., Ph.D., chief scientific officer at...
Allison Institute’s third annual scientific symposium highlighted by panel discussion with five Nobel laureates
Sessions focused on the latest advances in cancer vaccines, immunotherapy and immunology research
Symposium featured a panel discussion with...
Leading cancer research centers reinforce importance of safe and effective HPV vaccination to prevent cancer
62 NCI-designated cancer centers, leading national organizations and the University of Puerto Rico Comprehensive Cancer Center jointly endorse...
MD Anderson and Phoenix SENOLYTIX announce strategic cross-licensing agreement to enhance inducible switch technologies for cell and gene therapies
Agreement focuses on rimiducid, an agent used to activate certain safety switch technologies in cell therapies
Phoenix receives a supply of...
Novel tool helps identify key targets to strengthen CAR NK cell therapies
Researchers developed the first genome-wide CRISPR screening tool for primary human natural killer (NK) cells
Study revealed critical regulators...
Cancer-associated nerve injury leads to chronic inflammation and immunotherapy resistance
Study finds cancer cells break down protective nerve coverings, leading to nerve injury and chronic inflammation
These nerve injuries drive...
MD Anderson and TOPPAN Holdings announce strategic alliance to co-develop organoid technology for evaluating cancer treatments
3D cell culture technology may allow researchers to rapidly test a variety of treatments directly on patient biopsies
Teams will evaluate technology...